Executive SummaryELF Fibrosis Score
Executive Summary • Proprietary Blood Biomarker

Laboratory Test-Based Biomarker in MASH: Proprietary Test to Assess Liver Fibrosis

Executive summary of Enhanced Liver Fibrosis (ELF) staging cutoffs, FDA prognostic authorization, and clinical confounders.

What This Means for Patients

If your clinic doesn't have a FibroScan machine on site — or if body habitus makes ultrasound readings tricky — the ELF test lets your doctor check liver scarring from a single blood draw. Scores below 7.7 point toward minimal or no scarring, 9.8 or higher signals likely advanced fibrosis (F3+), and 11.3 or higher raises strong concern for cirrhosis and future liver complications.

Test Cutoffs Strengths Limitations
ELF™a F0/1: <7.71,2
≥F2: ≥7.7 to <9.81,2
≥F3: ≥9.81,2
F4: ≥11.31,2
  • Provides a single, readily-calculated score that stratifies fibrosis and progression risk1,3-5
  • ELF™ received FDA authorization to assess the likelihood of progression to cirrhosis and liver-related clinical events in patients with advanced fibrosis due to MASH6
  • ELF™ scores can be affected by age, sex, and other factors (eg, fluorescein and hemolyzed samples)6,7
  • While reflective of liver disease, biomarkers like HA may also respond to extrahepatic conditions (eg, renal dysfunction), potentially confounding interpretation8
  • Ability of the ELF™ score to monitor changes in fibrosis and MASH resolution is not well defined9